Since October, companies in the pharmaceutical field have successively announced monthly forecasts for the first three quarters. People's Daily Health Client sorted out the performance report and found that the overall performance of the pharmaceutical equipment sector was outstanding, including MGI Tech Co.,Ltd, Beijing Wantai Biological Pharmacy Enterprise, WuXi AppTec, and Sichuan Kelun Pharmaceutical, The net profit of Mgi Tech increased by more than 300% year-on-year.

MGI: Net profit increased by 311.8%-340.08% year-on-year

MGI, which landed in the A-share capital market on September 9, expects to achieve operating income of about 3.281 billion-3.441 billion CNY in the first three quarters of this year, a year-on-year increase of 15.26%-20.88%; it is expected to achieve attributable net profit of about 1.893 billion-2.023 billion 100 million CNY, a year-on-year increase of 311.8%-340.08%.

Regarding the growth of MGI's performance, the company said that it was mainly due to the development of the industry. The rapid development of the gene sequencing industry and the expansion of the application field of laboratory automation equipment have greatly increased the demand for the company's products; on the other hand, it has benefited from the company's years of research and development strength. Accumulation, management ability improvement and market channel expansion.

Wantai Bio: Bivalent cervical cancer vaccine continues to maintain both production and sales

On October 11, Wantai Bio released an announcement on the pre-increase in the first three quarters of 2022. It is expected that the net profit in the first three quarters will be 3.75 billion CNY to 3.95 billion CNY, a year-on-year increase of 216%-232%.

The announcement stated that the main reason for the expected increase in current performance is that the company's bivalent cervical cancer vaccine continued to maintain a boom in production and sales, and its revenue and profit grew rapidly; due to the impact of the new crown pneumonia epidemic at home and abroad, the company's COVID raw materials and COVID detection reagents The income and profit achieved Rapid growth.

WuXi AppTec: Strengthening R&D + Production, Doubled Net Profit

On October 12th, WuXi AppTec released the performance forecast for the first three quarters of 2022. In the first three quarters, the company is expected to achieve an operating income of about 28.395 billion CNY, a year-on-year increase of about 71.87%; it is expected to achieve a net profit of about 7.378 billion CNY, a year-on-year increase of about 107.12% .

Regarding the reasons for the company's performance growth, WuXi AppTec stated that the company continued to strengthen WuXi AppTec's unique integrated CRDMO (contract research, development and production) and CTDMO (contract testing, research and development and production) business models; Under the repeated influence, we will give full play to the advantages of global layout, multi-location operation and coverage of the whole industry chain, and timely formulate and efficiently implement business continuity plans to ensure the achievement of the company's overall performance goals.

Sichuan Kelun Pharmaceutical: Main infusion and non-infusion products market

Kelun Pharmaceutical predicts a net profit of 1.31-1.44 billion CNY in the first three quarters of 2022, a year-on-year increase of 55%-70%. The announcement shows that the company made every effort to expand the market of infusion and non-infusion products, continued to optimize product structure, and increased sales of newly approved products, resulting in a year-on-year increase in profit.

Jiangsu Kanion Pharmaceutical:  Based on traditional Chinese medicine, net profit increased by nearly 50%

According to the third quarter report of Kanion Pharmaceutical in 2022, the operating income was 1.028 billion CNY, a year-on-year increase of 26.25%; the net profit was 70.2172 million CNY, a year-on-year increase of 47.48%; the basic earnings per share was 0.12 CNY.

According to the data, Kanion Pharmaceutical is a company that focuses on the development of traditional Chinese medicine and actively deploys chemical drugs, biological drugs, and other fields. The company's main business involves the research and development, production, and sales of drugs.

Shenzhen Mindray Bio-Medical Electronics: Revenue and net profit remained stable

It was learned on October 11 that Mindray Bio-Medical Electronics disclosed the main operating data for the third quarter of 2022. According to preliminary calculations, the company is expected to achieve operating income of about 7.9 billion CNY in the third quarter, a year-on-year increase of about 20%. It is estimated that the net profit attributable to shareholders of the listed company About 2.8 billion CNY, a year-on-year increase of about 20%.

Regarding the reasons for the change in performance, Mindray Medical stated that in the third quarter of 2022, although it experienced the impact of the deterioration of the overseas economic situation and was affected by the repeated domestic epidemics, it benefited from the vigorous development of new domestic medical infrastructure and the continuous recovery of global routine business. At the same time, the company continued to strengthen internal management and continued to improve operating efficiency, achieving stable and healthy growth in the company's operating income and net profit.